Clinical Trials Using Anti-AG7 Antibody Drug Conjugate AbGn-107

Clinical trials are research studies that involve people. The clinical trials on this list are studying Anti-AG7 Antibody Drug Conjugate AbGn-107. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer

    This study is to define the safety profile and to determine the Maximal tolerated dose regimen and preliminary efficacy of AbGn-107 administered every 14 days (Q2W regimen) or 28 days (Q4W regimen) in patients with chemo-refractory locally advanced, recurrent or metastatic gastric, colorectal, pancreatic or biliary cancer.
    Location: 6 locations